肾移植术后免疫抑制剂治疗对人乳头瘤病毒感染及宫颈癌发生率的影响

目的:通过肾移植术后接受免疫抑制治疗的女性患者的人乳头瘤病毒(HPV)感染及宫颈癌发生率与同期我院妇科女性患者的对比,探讨肾移植术后免疫抑制治疗对女性高危型HPV感染及宫颈癌发生率的影响,为肾移植术后患者高危型HPV感染和宫颈癌的早期诊断和防治提供依据。方法:选取在我院行肾移植术的女性患者中,无其他器官移植,移植前无HPV感染、宫颈上皮内瘤变(CIN)及宫颈癌的患者865例作为研究组,选取我院妇科同期未进行器官移植的患者作为对照组,比较分析2组高危型HPV感染和宫颈癌发病情况。结果:研究组患者的高危型HPV感染率、CINⅢ及宫颈癌发生率均高于对照组,差异有统计学意义(均P<0.001);而研究组中高危型HPV感染、CINⅢ及宫颈癌的平均发病年龄与对照组比较差异均无统计学意义(均P>0.05)。结论:肾移植术后免疫抑制治疗不会使患者HPV感染及宫颈癌的发病年龄提前,但可能导致发生率增高。

Effect of Immunosuppressive Therapy on HPV Infection and the Incidence of Cervical Cancer after Renal Transplantation

Objective: By studying the human papilloma virus (HPV) infection rate and cervical cancer incidence in women on immunosuppressive therapy after renal transplantation, compared with that of the gynecological patients, to explore the immunosuppressive therapy effect on high risk type HPV infection and cervical cancer incidence in women after renal transplantation, and provide evidence for early diagnosis and prevention of cervical cancer. Methods: Selection in female patients with renal transplantation, no other organ transplantation, before transplantation without HPV infection and CIN and cervical cancer patients 865 cases as study group. Select gynecological patents in our hospital without organ transplant at the same time as control group. Comparative analysis of the two groups of high-risk HPV infection and cervical cancer incidence. Results:The high-risk HPV infection rate and the incidence of CINⅢand cervical cancer in study group were higher than that in control group, difference was statistically significant (all P<0.001);And the average onset age in high-risk HPV infection, CINⅢ and cervical cancer had no statistical significance difference in the two groups (all P>0.05). Conclusions:Immunosuppressive therapy after renal transplantation will not make early onset age in HPV infection and cervical cancer, but may result in increased incidence of the disease.